HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation
Status:
Withdrawn
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
This is a non-randomised, open-label phase I study of an investigational medicinal product
(IMP) consisting of a HLA-A*02:01 restricted HA-1H T cell receptor transduced T cell
(MDG1021) immunotherapy for relapsed or persistent hematologic malignancies after allogeneic
hematopoietic stem cell transplantation. The aim of the study is to determine the recommended
phase II dose of MDG1021.